AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02294175 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bedside Sharp Debridement
Description: The use of a sharp clinical instrument (currette, scalpel, scissors, forceps) by a qualified clinician to remove necrotic tissue and bacterial biofilm from an open chronic wound
Study NCT04216446 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Health Intervention
Description: A mobile based application will be developed that will function on android as well as the iPhone operating system. The application will be provided to eligible pregnant women randomized to the intervention group. The dietary, supplement use and physical activity coaching will be provided over the period of 6 months through the application.
Study NCT02945397 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group-based activity
Description: Regular follow-up from welfare authority as well as a 3 month group activity with weekly gatherings, focusing on coping, goal-setting and relevant information regarding available public services.
Study NCT02945397 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individual activity
Description: Regular follow-up from welfare authority as well as a 3 month membership card at a given gym.
Study NCT02826265 — intervention group
Intervention type: DEVICE
Intervention: multiple breath washout test (MBW)
Study NCT02826265 — intervention group
Intervention type: DEVICE
Intervention: impulse oscillometry (IOS)
Study NCT02826265 — intervention group
Intervention type: DEVICE
Intervention: body plethysmography (BP)
Study NCT02826265 — intervention group
Intervention type: DEVICE
Intervention: quantitative computed tomography (qCT)
Description: ultra-low-dose qCT
Study NCT01877382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milademetan
Description: DS-3032b will be administered as an oral capsule. It will be supplied in 5, 20, 80, and/or 200 mg capsules individually packaged in desiccant-embedded aluminum blisters.
Study NCT01877382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milademetan
Description: Milademetan will be administered as a single oral capsule or as a combination of multiple oral capsules containing 5, 20, 80, and/or 200 mg. An alternate combination of 30 and/or 100 mg capsules of milademetan may be utilized.
Study NCT02262000 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Image Guided Stereotactic Ablative Radiotherapy
Study NCT02402634 — intervention group
Intervention type: OTHER
Intervention: Mechanical ventilatory lung care
Study NCT04586218 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer guided vasopressor infusion
Description: automated titration of vasopressor infusion to maintain a mean arterial pressure > 65mmHg
Study NCT04586218 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Manual control of vasopressor infusion
Description: manual adjustments of noradrenaline infusion
Study NCT00663897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lansoprazole
Description: lansoprazole, 30 mg, once daily for 14 days
Study NCT00663897 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mosapride
Description: mosapride, 5 mg, thrice daily for 14 days
Study NCT00326781 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicoderm Transdermal Patch
Description: The dosing schedule is as follows: 4 weeks of 21mg per 24 hours, 2 weeks of 14mg per 24 hours, and 2 weeks of 7mg per 24 hours. Treatment lasted 8 weeks.
Study NCT00326781 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine Nasal Spray
Description: 8 weeks of self-administered nicotine nasal spray at 40 recommended doses per day, tapering by 1/3 for the last 4 weeks. Nasal spray dosing was 0.5 mg spray per nostril (1 mg) for a maximum of 5 doses per hour and 40 doses per day. This dosing schedule is based on the average nicotine intake per cigarette of 1 mg per cigarette. Treatment lasted 8 weeks.
Study NCT03990935 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ginger and rosemary gel
Description: First the participant will be asked to brush his/her teeth thoroughly with 1450 ppm fluoride toothpaste (Colgate total healthy clean toothpaste). Then an application of a thin ribbon of this gel to the teeth using a brush. The medication will be left for at least 1 minute. The participant will be asked to spit out the medication after use and not to swallow it. Also the participant will be asked not to rinse his/her mouth, eat, or drink for at least 30 minutes after use to get the best results.
Study NCT03990935 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ginger and rosemary gel
Description: First the participant will be asked to brush his/her teeth thoroughly with 1450 ppm fluoride toothpaste (Colgate total healthy clean toothpaste). Then an application of a thin ribbon of this gel to the teeth using a brush. The medication will be left for at least 1 minute. The participant will be asked to spit out the medication after use and not to swallow it. Also the participant will be asked not to rinse his/her mouth, eat, or drink for at least 30 minutes after use to get the best results.
Study NCT03295552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: decitabine 7mg/m2, d1-d5, q3w
Study NCT03295552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: carboplatin AUC = 6, d6, q3w
Study NCT01091545 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: DBT and FFDM
Description: Women in the study will once undergo both standard FFDM screening (2-views) and DBT (1 view, MLO). This will result in a doubled radiation dose compared to only 2-view FFDM, which is the standard procedure for women in the screening program.
Study NCT00900731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol 150 μg
Description: Indacaterol 150 μg was provided in powder filled capsules with a single dose dry powder inhaler (SDDPI).
Study NCT00900731 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium 18 μg
Description: Tiotropium 18 μg was provided in powder filled capsules with the manufacturer's proprietary inhalation device (HandiHaler®).
Study NCT00900731 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to indacaterol
Description: Placebo to indacaterol was provided in powder filled capsules with a single dose dry powder inhaler (SDDPI).
Study NCT00900731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to tiotropium
Description: Placebo to tiotropium was provided in powder filled capsules with the manufacturer's proprietary inhalation device (HandiHaler®).
Study NCT01763723 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IPL-home use device
Description: A light based home use device for hair removal
Study NCT03944733 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Iron
Description: 65 mg of iron (ferrous sulfate)
Study NCT03944733 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Gelatin
Description: 600 mg gelatin
Study NCT01914159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab (Lucentis, Novartis Pharma GmbH, Germany)
Description: Monthly intravitreal injections
Study NCT04375904 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Image-Guided Stereotactic Ablative Radiotherapy (IG-SABR)
Description: Image-Guided Stereotactic Ablative Radiotherapy (IG-SABR) delivered in 8 fractions of 7.5 Gy. OAR constraints must be respected but a minimum dose coverage to 95% of the PTV will be allowed down to 75% and a minimum dose to 99% of the GTV allowed at 75%. Respiratory monitoring/active respiratory management will be used. Plans will be created and delivered using photon beams with energies between 6-10 MV.
Study NCT01752153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desferrioxamine, Legalon® (Silymarin)
Description: Desferrioxamine (Novartis Pharma AG, Switzerland) at the dose of 40 mg/Kg/day and Legalon® tablets (Madaus Pharma, Italy)
Study NCT01752153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silymarin (Legalon)
Study NCT02553785 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Revivent TC
Study NCT03639805 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music therapy program MUSIC CARE® + standard care
Description: Administration of a specific music therapy program (U method) delivered through headphones from an iPad, under the direction of trained nurses. The program will be proposed 3 times a day and will last 20 minutes at each session.
Study NCT03639805 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard care of vaso-occlusive crises
Description: administration of standard care only
Study NCT01947426 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: DHA Supplementation
Description: mothers consuming 400 mg of DHA/day and their neonates
Study NCT01947426 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control (milk without DHA)
Description: mothers consuming placebo product and their neonates
Study NCT04346212 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Swallowing evaluation with the EAT-10 and the volume-viscosity swallowing test (V-VST)
Description: We will assess dysphagia, nutritional status and needs of compensatory treatment (fluid and nutritional adaptation) in patients with COVID-19 disease. We will also collect clinical data, information about swallowing and nutritional status and needs through the electronical medical history of the patients and by telephone call at 3 and 6 months follow-up, as well as clinical complications.
Study NCT04476121 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PRF application
Description: PRF application into post-operative wound.
Study NCT04476121 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nipas application
Description: Nipas application into post-operative wound.
Study NCT00602290 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Citalopram
Description: Citalopram dosage will be 20 to 60 mg a day prior to FDA warning limiting it to 20-40 mg in 2011. Participants will begin taking one 20-mg capsule once per day for 4 weeks, and this dosage may be increased or decreased depending on the participant's response to the medication or side-effect profile. Participants will continue on their assigned dosage of citalopram that will be titrated up after week 4 if clinical global impressions (CGI) scores were > 2 until treatment completion.
Study NCT00602290 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate (MPH)
Description: MPH dosage will be 5 to 40 mg a day. Participants will initially take 1 capsule (2.5 mg) twice per day, which will be increased to a maximum up to 8 x 2.5 mg capsules twice per day. After Visit 11, MPH dosage will be gradually reduced over 2 weeks until participants are no longer taking any capsules.
Study NCT00602290 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo pills will be taken in combination with the active pills. Participants will initially take 1 capsule twice per day, which will be increased to a maximum of 16 capsules twice per day matching methylphenidate, and 1-3 capsules matching citalopram. After Visit 11, placebo dosage will be gradually reduced over 2 weeks until participants are no longer taking any capsules.
Study NCT03191864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APT-1011
Description: APT-1011 is an orally disintegrating tablet formulation of fluticasone propionate
Study NCT03191864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets are identical in composition to APT-1011 except they exclude the active ingredient.
Study NCT03191864 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets are identical in composition to APT-1011 except they exclude the active ingredient.
Study NCT02267135 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg
Description: Secukinumab 300 mg will be provided in 1 mL prefilled syringes of 150 mg. Each dose of 300 mg secukinumab will consist of two secukinumab 150 mg injections once weekly for 5 weeks (Baseline, Weeks 1, 2, 3 and 4), followed by dosing every four weeks starting at Week 8 through Week 20 inclusive. In order to maintain the blinding, patients will receive additional placebo injections at Weeks 13, 14 and 15. The patients (or caregivers) will self-inject each dose at the study site under the supervision of site personnel when injections occur of days of study visits. The injections not occurring during a study visit will be done by the patients (or caregivers) at home.
Study NCT02267135 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be provided in 1 mL prefilled syringe. Each placebo dose will consist of two placebo injections once weekly for five weeks (Baseline, Weeks 1, 2, 3 and 4), then after four weeks at Week 8. At Week 12, PSSI responders will continue on placebo and receive their injections once weekly for five weeks (Weeks 12, 13, 14, 15 and 16), then followed by dosing after four weeks at Week 20. PSSI non-responders will be switched to receive 300 mg secukinumab at Weeks 12, 13, 14, 15 and 16, then after four weeks at Week 20. The patients (or caregivers) will self-inject each dose at the study site under the supervision of site personnel when injections occur on days of study visits. The injections not occurring during a study visit will be done by the patients (or caregivers) at home.
Study NCT01527487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin
Description: 1.4 mg/m2 IV (Days 1 \& 8), given short (≤15 minute) IV infusion, per institutional standard
Study NCT01527487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be given as an IV infusion (600 mg/m2) on Day 1 of each treatment cycle over approximately 30 minutes, or per institutional standard.
Study NCT01527487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Patients assigned to Treatment Arm 2 will receive docetaxel 75 mg/m2 IV on Day 1 of each treatment cycle every 3 weeks.
Study NCT04182568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel followed by anthracycline and cyclophosphamide
Description: nab-paclitaxel 260mg/m2 for every 2 weeks followed by anthracycline and cyclophosphamide
Study NCT04182568 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel followed by anthracycline and cyclophosphamide
Description: Docetaxel 100 mg/m2 for for every 2 weeks followed by anthracycline and cyclophosphamide
Study NCT02289846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IW-9179
Study NCT02289846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo
Study NCT02289846 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Study NCT02312453 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Posterior approach
Description: We adopted the technique as described by Hebbard et al.
Study NCT03395717 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exoskeleton-Assisted Gait Training
Study NCT00427206 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: acetaminophen (4g/day)
Study NCT00427206 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT02823834 — intervention group
Intervention type: DEVICE
Intervention: PROFEMUR® Gladiator Plasma Femoral Stems
Description: THA using PROFEMUR® Gladiator Plasma stems and PROCOTYL® L Beaded Acetabular Components
Study NCT04574934 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aquatic therapy
Description: Aquatic therapy refers to water-based treatments or exercises of therapeutic intent, in particular for relaxation, fitness, and physical rehabilitation. Treatments and exercises are performed while floating, partially submerged, or fully submerged in water. Many aquatic therapy procedures require constant attendance by a trained therapist and are performed in a specialized temperature-controlled pool. Rehabilitation commonly focuses on improving the physical function associated with illness, injury, or disability
Study NCT03018366 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 17beta Estradiol
Description: Participants will use a dose of transdermal estradiol 0.1 mg/day patch for 12 weeks +/- 1week. PAT index vascular measures and serum immune markers will be measured after 6 and 12 weeks +/- 1week on estrogen patches. Patches will be applied by the participant to the lower abdomen twice weekly, alternating sides.
Study NCT03018366 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Transdermal placebo patch
Description: Participants will use a dose of placebo patches for 12 weeks +/- 1 week. Placebos will be applied by the participant to the lower abdomen twice weekly, alternating sides.
Study NCT03018366 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone
Description: After 12 weeks +/- 1week of transdermal estradiol patch, participants will use estrogen patch plus progesterone for 2 additional weeks +/- 3 days. Progesterone is a peanut based product and for patients with a peanut allergy we will replace this with a synthetic progestin at an equivalent dose, medroxyprogesterone 10mg.
Study NCT03018366 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Pill
Description: After 12 weeks +/- 1week of transdermal placebo patch, participants will use placebo patch plus placebo pill for 2 additional weeks +/- 3 days.
Study NCT02607852 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: iPads
Description: The current study will help determine if using Burn Outcomes Questionnaire and 17- item Pediatric Symptom Checklist (PSC-17) feedback data, collected on iPads or online, over the course of patient treatment will be useful for the physicians and ultimately impact the recovery of the patient.
Study NCT01093183 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT01093183 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT04358068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ)
Description: Administered orally
Study NCT04358068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin (Azithro)
Description: Administered orally
Study NCT04561024 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: AI model
Description: Deep Learning CNN model
Study NCT04096443 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal microbial transplant (FMT)
Description: Oral fecal microbial transplant capsules
Study NCT01976468 — intervention group
Intervention type: OTHER
Intervention: SCC metastasis
Description: occurrence of SCC metastasis
Study NCT03144843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib 500mg, po, qd, every 4 weeks Paclitaxol: 80mg/m2, d1, d8, d15, every 4 weeks
Study NCT03144843 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo: 500mg, po, qd, every 4 weeks Paclitaxol: 80mg/m2, d1, d8, d15, every 4 weeks
Study NCT03053648 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-acupressure
Description: The subjects will be told to perform self-acupressure 30 min before sleep for 20 min every night for 4 weeks. Telephone follow-up will be made twice a week by the trained student research assistant during the 4-week treatment period to remind subjects to practice self-acupressure.
Study NCT03053648 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sleep hygiene education
Description: A training hand-out will be provided to each subject. The hand-outs included manualized sleep hygiene instructions. A registered nurse who has been trained by a clinical psychologist will be the instructor on sleep hygiene and activity scheduling. To enhance interaction and ensure the quality of teaching, each course will be conducted in a group of 5 participants.
Study NCT06318052 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The FemTouch delivery system
Description: The FemTouch delivery system is used in conjunction with the AcuPulse CO2 laser system and the AcuScan120 microscanner to provide fractional treatments in gynecology
Study NCT06318052 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gynomunal gel treatment
Description: hormone/free, vaginal moisturizing gel for women with vaginal dryness
Study NCT01300299 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: 12 Gray (Gy) x 4 fractions (48 Gy) will be delivered to peripherally located tumors (> 2 cm in all directions around the proximal bronchial tree and centrally located tumors (within \<2 centimeters (cm) of proximal bronchial tree). Treatment should be given on consecutive days. There will be 4 or 5 treatments.
Study NCT02152553 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone
Study NCT02152553 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00751257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Description: 2400mg (1200mg b.i.d., 600mg capsules, p.o.)
Study NCT00751257 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identically appearing placebo capsules, packaged in an N-acetylcysteine slurry so that placebo has similar odor as active NAC capsules
Study NCT01497886 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Hip Hop Stroke educational program
Description: Three one-hour sessions, conducted over three consecutive days